Filter
26
Text search:
vector-based
vaccine
Featured
5
2
Language
Document type
10
5
3
2
2
1
1
1
1
Countries / Regions
2
2
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
7
2
1
Toolboxes
16
4
3
1
1
1
1
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence s
...
22 December 2020
The COVID-19 vaccine safety guidance manual has been developed upon recommendation and guidance of GACVS members, as well as by experts incorporating current and available information critical to all stakeholders when COVID-19 vac
...
Published:February 02, 2021DOI:https://doi.org/10.1016/S0140-6736(21)00234-8
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and a
...
27 September 2022
These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the b
...
Mass vaccination campaigns to prevent coronavirus disease 2019 (Covid-19) are occurring in many countries; estimates of vaccine effectiveness are urgently needed
to support decision making. A countrywide mass vaccination campaign with the
use of
...
This document provides guidance on interventions to prevent vaccine-preventable disease outbreaks in the context of mass population movement resulting from the ongoing crisis in Ukraine.
first issued 18 August 2022
The Committee examined the clinical development of Ebola virus vaccines and conducted an inventory of available data on their safety. It also reviewed 3 generic issues: updating a global strategy on vaccine saf
...
6 June 2022
These WHO interim recommendations on the use of the Janssen Ad26.COV2.S (COVID-19) vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included
...
the Lancet : Published Online July 31, 2015 http://dx.doi.org/10.1016/S0140-6736(15)61117-5
interim guidance, 19 July 2021 (arabic version)
(Первинна та бустерна вакцинації) – з векторною вакциною – (вакцина Janssen® від COVID-19 виробництва Janssen Cilag International/Johnson & Johnson
Станом на: 14 лютого 2022 р. (даний інформаційн
...
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
The report presents current information (updated to September 2015) on candidate vaccines, therapies and medical devices for Ebola and gives an overview of completed and on-going trials.
AstraZeneca-SKBio in South Korea and Serum Institute of India
Orientations provisoires 19 juillet 2021
– векторною вакциною – (Janssen® від COVID-19 виробництва Janssen Cilag International/Johnson & Johnson)
Anamnese zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019) (Grundimmunisierung und Auffrischimpfungen)
– mit Vektor-Impfstoff – (COVID-19
...
